THE ROLE OF GROWTH AND TRANSCRIPTION FACTORS IN EVALUATING THE EFFECTIVENESS OF NEOADYUVANTNOY CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

The study was undertaken to analyse molecular markers associated with clinical response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. the purpose of the study was to determine the relationship between the expression of transcription factors, vascular endothelial growth factor (VEGF), activity of proteasomes and calpaines in tumors and the response to neoadjuvant chemotherapy of patients with muscle-invasive bladder cancer. material and methods. The study included 50 patients with histologically verified transitional cell carcinoma of the bladder T_2a–3bN₀M₀ (G₂-G₃). The levels of transcription and growth factors were determined by an immunoenzymatic assay. Proteasome activity was measured using the fluorometric method. results. Patients who achieved partial tumor regression demonstrated higher levels of VEGF and transcription factors (NF-κB and HIF-1), but lower levels of the 26S proteasome compared to those observed in patients with stable disease. Conclusion. Additional molecular markers that can be considered as predictors of response to neoadjuvant chemotherapy for bladder cancer were identified.

1. Takhauov R.M., Choinzonov E.L., Pisareva L.F., Karpov A.B., Odintsova I.N. The incidence of malignant tumors of the population of Tomsk region. Zdravookhranenie Rossiiskoi Federatsii. 2003; 2: 30–32. [in Russian]

2. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignancies in Russia in 2014. Moscow, 2016; 236. [in Russian]

3. Vintizenko S.I., Slonimskaya E.M., Usynin. E.A., Yurmazov Z.A., Khursevich N.A. Neoadjuvant chemotherapy in the treatment of organmuscle-invasive bladder cancer. Siberian Journal of Oncology. 2009; 2: 21–24. [in Russian]

4. Volkova M.I., Matveev V.B., Medvedev S.V., Nosov D.A., Figurin K.M., Chmielewski E.V., Chernyaev V.A. Clinical guidelines for the diagnosis and treatment of bladder cancer patients. Moscow. 2014. [in Russian]

5. Popov А.М., Karyakin О.B. Organ-preserving treatment of invasive bladder cancer. Russian Journal of Oncology. 2005; 3: 49–52. [in Russian]

6. Sternberg C.N. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? Ann Oncol. 2002; 13 Suppl 4: 273–9.

7. Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: longterm results of the BA06 30894 trial. J Clin Oncol. 2011 Jun 1; 29 (16): 2171–7. doi: 10.1200/JCO.2010.32.3139.

8. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., deVere White R.W., Sarosdy M.F., Wood D.P. Jr., Raghavan D., Crawford E.D. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349 (9): 859–66.

9. Takata R., Obara W., Fujioka T. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer. Aktuelle Urol. 2010 Jan; 41 Suppl 1: S41–5. doi: 10.1055/s-0029-1224655.

10. Fergelot P., Rioux-Leclercq N., Patard J.J. Molecular Pathways of tumour angiogenesis and new targeted therapeutical approches in renal cancer. Prog Urol. 2005; 15 (6): 1021–1029.

11. García-Closas M., Malats N., Real F.X., Yeager M., Welch R., Silverman D., Kogevinas M., Dosemeci M., Figueroa J., Chatterjee N., Tardón A., Serra C., Carrato A., García-Closas R., Murta-Nascimento C., Rothman N., Chanock S.J. Large-scale evaluation of candidate genes identifies association between VEGF polymorphism and bladder cancer risk. PLoS Genet. 2007 Feb 23; 3 (2): e29. doi: 10.1371/journal.pgen.0030029.

12. Goddard J.C., Sutton C.D., Furness P.N., O’Byrne K.J., Kockelbergh R.C. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res. 2003 Jul; 9 (7): 2583–6.

13. Juvekar A., Manna S., Ramaswami S., Chang T.P., Vu H.Y., Ghosh C.C., Celiker M.Y., Vancuriva I. Bortezomib induces nuclear translocation of IkBα resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res. 2011 Feb; 9 (2): 183–94. doi: 10.1158/1541-7786.MCR-10-0368.

14. Spirina L.V., Kondakova I.V., Choynzonov E.L., Chigevskaya S.Y., Shishkin D.A., Kulbakin D.Y. Expression of vascular endothelial growth factor and transcription factors HIF-1 and NF-κB expression in squamous cell carcinoma of head and neck; association with proteasome and calpains activity. J Cancer Res Clin Oncol. 2013 Apr; 139(4): 625–33. doi: 10.1007/s00432-012-1366-0.

15. Wu W.K., Volta V., Cho C.H., Wu Y.C., Li H.T., Yu. L., Li Z.J., Sung J.J. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem Biophys Res Commun. 2009 Sep 4; 386(4): 598–601. doi: 10.1016/j.bbrc.2009.06.080.

16. Yue C.X., Ma J., Zhou H.J., Tang Q.L., Li L.L., Bi F., Xue Y. The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011 Jul; 42(4): 445–50.

17. Spirina L.V., Kondakova I.V., Usynin Y.A., Vintizenko S.I. Angiogenesis regulation in renal and bladder cancers. Siberian Journal of Oncology. 2008; 28: 65–70. [in Russian]

18. Kondakova I.V., Spirina L.V., Koval V.D., Shashova E.E., Choinzonov E.L., Ivanova E.V., Kolomiets L.A., Chernyshova A.L., Slonimskaya E.M., Usynin E.A., Afanas’ev S.G. Chymotrypsin-like activity and subunit composition of proteasomes in human cancers. Mol. Biol. 2014; 48 (3): 444–451. [in Russian]